RE: Commercial 2021 not 20227 Dec 2020 16:30
First of all Elrico thank you for enquiring and responding, very much appreciated and sorry if I am being a bit thick. From the March half year RNS Any licensed products resulting from these agreements will be sold to Croda's global portfolio of Personal Care customers, which amount to >12,000, some of which are the leading companies and brands in the market. "SkinBioTherapeutics will be paid tiered royalties based on global sales revenues on any licensed products subsequently derived from the successful development of the partnership. Recognising the development activity required by Croda, the Company anticipates revenue generation to commence from these additional agreements during 2021."
From the End of Year results RNS "The project is progressing in line with the original plan and has not been adversely impacted by COVID-19. On the basis of continued progress, the Company anticipates licensed royalty revenue generation to commence in 2022.".
So is the company saying that there will be some non-royalty based revenue generated in 2021 and that explains the apparent difference in the two RNS statements?